Investment
Features
FeesSafety
Academy
More
Pluang+

Electro Optic Systems surges on A$700M drone defense contract and strong growth outlook

Market News
19 Oct 2026
Seeking Alpha
View Source
Bullish
Electro Optic Systems surges on A$700M drone defense contract and strong growth outlook

Electro Optic Systems (EOS), an Australian leader in drone defense technology, has secured a A$700 million contract for its MARSS drone defense system, boosting its backlog to A$1.55 billion. The company’s valuation is mainly driven by its Remote Weapon Stations business, but its laser and MARSS segments are gaining recognition due to strong growth prospects and major contracts. EOS expects to deliver 80% of its backlog within 12–24 months with a 20% EBITDA margin, supporting a robust growth trajectory. The company’s share price has increased sixfold over five years, and successful delivery of the laser contract with the Dutch army could accelerate this growth further.

Electro Optic Systems' recent contract and backlog growth provide context for readers interested in industrials. For readers following the Industrials sector, here is Pluang's market snapshot as of Oct 20, 2026 04:11 WIB: Of 135 priced US Industrials stocks, 45 rose and 89 fell. Notable movers include MMM (3M Company) at USD 170.03 with a 1-day change of +3.22% and a typical hold time on Pluang of 170 days, HONA (Honeywell Aerospace Inc.) at USD 162.74 down 3.18% with 100% sell order activity, and ADT Inc at USD 6.81 up 3.18% with a typical hold time of 62 days. The most notable figure is the 100% sell order activity for HONA.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
16 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
16 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App